Skip to main content
Journal cover image

Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial.

Publication ,  Journal Article
Dore, GJ; Feld, JJ; Thompson, A; Martinello, M; Muir, AJ; Agarwal, K; Müllhaupt, B; Wedemeyer, H; Lacombe, K; Matthews, GV; Schultz, M; Kho, D ...
Published in: J Hepatol
March 2020

BACKGROUND & AIMS: Direct-acting antiviral (DAA) therapy for HCV has high efficacy and limited toxicity. We hypothesised that the efficacy of glecaprevir-pibrentasvir for chronic HCV with a simplified treatment monitoring schedule would be non-inferior to a standard treatment monitoring schedule. METHODS: In this open-label multicentre phase IIIb trial, treatment-naïve adults with chronic HCV without cirrhosis were randomly assigned (2:1) to receive glecaprevir-pibrentasvir 300 mg-120 mg daily for 8 weeks administered with a simplified or standard monitoring strategy. Clinic visits occurred at baseline and post-treatment week 12 in the simplified arm, and at baseline, week 4, week 8, and post-treatment week 12 in the standard arm. Study nurse phone contact occurred at week 4 and week 8 in both arms. Participants requiring adherence support were not eligible, including those reporting recent injecting drug use. The primary endpoint was sustained virological response at post-treatment week 12 (SVR12), with a non-inferiority margin of 6%. RESULTS: Overall, 380 participants (60% male, 47% genotype 1, 32% genotype 3) with chronic HCV were randomised and treated with glecaprevir-pibrentasvir in the simplified (n = 253) and standard (n = 127) arms. In the intention-to-treat population, SVR12 was 92% (95% CI 89%-95%) in the simplified and 95% (95% CI 92%-99%) in the standard arm (difference between arms -3.2%; 95% CI -8.2% to 1.8%) and did not reach non-inferiority. In the per-protocol population, SVR12 was 97% (95% CI 96%-99%) in the simplified and 98% (95% CI 96%-100%) in the standard arm. No treatment-related serious adverse events were reported. CONCLUSIONS: In patients with chronic HCV infection without cirrhosis, treatment with glecaprevir-pibrentasvir was safe and effective. In comparison to standard monitoring, a simplified monitoring schedule did not achieve non-inferiority. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT03117569. LAY SUMMARY: Direct-acting antiviral (DAA) therapy for hepatitis C is highly effective and well tolerated. The SMART-C randomised trial evaluated an 8-week regimen of glecaprevir-pibrentasvir for hepatitis C treatment, using a simplified monitoring schedule that included no pathology tests or clinic visits during treatment. This simplified strategy produced a high cure rate (92%), but this was not equivalent to the standard monitoring schedule cure rate (95%).

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Hepatol

DOI

EISSN

1600-0641

Publication Date

March 2020

Volume

72

Issue

3

Start / End Page

431 / 440

Location

Netherlands

Related Subject Headings

  • Young Adult
  • Sustained Virologic Response
  • Sulfonamides
  • Quinoxalines
  • Pyrrolidines
  • Proline
  • Middle Aged
  • Medication Adherence
  • Male
  • Leucine
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Dore, G. J., Feld, J. J., Thompson, A., Martinello, M., Muir, A. J., Agarwal, K., … SMART-C Study Group. (2020). Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial. J Hepatol, 72(3), 431–440. https://doi.org/10.1016/j.jhep.2019.10.010
Dore, Gregory J., Jordan J. Feld, Alex Thompson, Marianne Martinello, Andrew J. Muir, Kosh Agarwal, Beat Müllhaupt, et al. “Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial.J Hepatol 72, no. 3 (March 2020): 431–40. https://doi.org/10.1016/j.jhep.2019.10.010.
Dore GJ, Feld JJ, Thompson A, Martinello M, Muir AJ, Agarwal K, et al. Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial. J Hepatol. 2020 Mar;72(3):431–40.
Dore, Gregory J., et al. “Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial.J Hepatol, vol. 72, no. 3, Mar. 2020, pp. 431–40. Pubmed, doi:10.1016/j.jhep.2019.10.010.
Dore GJ, Feld JJ, Thompson A, Martinello M, Muir AJ, Agarwal K, Müllhaupt B, Wedemeyer H, Lacombe K, Matthews GV, Schultz M, Klein M, Hezode C, Mercade GE, Kho D, Petoumenos K, Marks P, Tatsch F, Dos Santos AGP, Gane E, SMART-C Study Group. Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial. J Hepatol. 2020 Mar;72(3):431–440.
Journal cover image

Published In

J Hepatol

DOI

EISSN

1600-0641

Publication Date

March 2020

Volume

72

Issue

3

Start / End Page

431 / 440

Location

Netherlands

Related Subject Headings

  • Young Adult
  • Sustained Virologic Response
  • Sulfonamides
  • Quinoxalines
  • Pyrrolidines
  • Proline
  • Middle Aged
  • Medication Adherence
  • Male
  • Leucine